Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre tria... von Johnsen, Peter Holger, Hilpüsch, Frank, Cavanagh, Jorunn Pauline, Leikanger, Ingrid Sande, Kolstad, Caroline, Valle, Per Christian, Goll, Rasmus

Volltext

Beyond the regional average: Drivers of geographical rainfall variability during East Africa's short rains von Kolstad, Erik W., Parker, Douglas J., MacLeod, David A., Wainwright, Caroline M., Hirons, Linda C.

Volltext

The 2019–21 drought in southern Madagascar von Barimalala, Rondrotiana, Wainwright, Caroline, Kolstad, Erik W., Demissie, Teferi D.

Volltext

Radioimmunotherapy of Non-Hodgkin B-cell Lymphoma: An update von Cicone, Francesco, Santo, Giulia, Bodet-Milin, Caroline, Cascini, Giuseppe Lucio, Kraeber-Bodéré, Françoise, Stokke, Caroline, Kolstad, Arne

Volltext

Infiltration of CD163‐, PD‐L1‐ and FoxP3‐positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors von Rodrigues, Joana M., Nikkarinen, Anna, Hollander, Peter, Weibull, Caroline E., Räty, Riikka, Kolstad, Arne, Amini, Rose‐Marie, Porwit, Anna, Jerkeman, Mats, Ek, Sara, Glimelius, Ingrid

Volltext

FDG PET/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma—Are We Hitting the Target? von Løndalen, Ayca, Blakkisrud, Johan, Revheim, Mona-Elisabeth, Dahle, Jostein, Kolstad, Arne, Stokke, Caroline

Volltext

FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma von Løndalen, Ayca, Blakkisrud, Johan, Revheim, Mona-Elisabeth, Madsbu, Ulf Erik, Dahle, Jostein, Kolstad, Arne, Stokke, Caroline

Volltext

Myelosuppression in patients treated with 177 Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable von Blakkisrud, Johan, Løndalen, Ayca, Dahle, Jostein, Martinsen, Anne Catrine, Kolstad, Arne, Stokke, Caroline

Volltext

Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable von Blakkisrud, Johan, Løndalen, Ayca, Dahle, Jostein, Martinsen, Anne Catrine Trægde, Kolstad, Arne, Stokke, Caroline

Volltext

Myelosuppression in patients treated with 177Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable von Blakkisrud, Johan, Løndalen, Ayca, Dahle, Jostein, Martinsen, Anne Catrine, Kolstad, Arne, Stokke, Caroline

Volltext

Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma von Nikkarinen, Anna, Lokhande, Lavanya, Amini, Rose-Marie, Jerkeman, Mats, Porwit, Anna, Molin, Daniel, Enblad, Gunilla, Kolstad, Arne, Räty, Riikka, Hutchings, Martin, Weibull, Caroline E., Hollander, Peter, Ek, Sara, Glimelius, Ingrid

Volltext

Biodistribution and dosimetry results from a phase 1 trial of therapy with the antibody-Radionuclide conjugate 177Lu-Lilotomab satetraxetan von Blakkisrud, Johan, Holtedahl, Jon Erik, Løndalen, Ayca, Dahle, Jostein, Bach-Gansmo, Tore, Holte, Harald, Nygaard, Stine, Kolstad, Arne, Stokke, Caroline

Volltext

Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients von Stokke, Caroline, Blakkisrud, Johan, Løndalen, Ayca, Dahle, Jostein, Martinsen, Anne Catrine Trægde, Holte, Harald, Kolstad, Arne

Volltext

Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan von Blakkisrud, Johan, Holtedahl, Jon Erik, Løndalen, Ayca, Dahle, Jostein, Bach-Gansmo, Tore, Holte, Harald, Nygaard, Stine, Kolstad, Arne, Stokke, Caroline

Volltext

Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177 Lu-Lilotomab Satetraxetan von Blakkisrud, Johan, Holtedahl, Jon Erik, Løndalen, Ayca, Dahle, Jostein, Bach-Gansmo, Tore, Holte, Harald, Nygaard, Stine, Kolstad, Arne, Stokke, Caroline

Volltext

Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody–Radionuclide Conjugate ^sup 177^Lu-Lilotomab Satetraxetan von Blakkisrud, Johan, Holtedahl, Jon Erik, Løndalen, Ayca, Dahle, Jostein, Bach-Gansmo, Tore, Holte, Harald, Nygaard, Stine, Kolstad, Arne, Stokke, Caroline

Volltext

Red Marrow–Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177 Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody–Radionuclide Conjugate von Blakkisrud, Johan, Løndalen, Ayca, Dahle, Jostein, Turner, Simon, Holte, Harald, Kolstad, Arne, Stokke, Caroline

Volltext

Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with ^sup 177^Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate von Blakkisrud, Johan, Løndalen, Ayca, Dahle, Jostein, Turner, Simon, Holte, Harald, Kolstad, Arne, Stokke, Caroline

Volltext

Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with super( 177)Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate von Blakkisrud, Johan, Loendalen, Ayca, Dahle, Jostein, Turner, Simon, Holte, Harald, Kolstad, Arne, Stokke, Caroline

Volltext

Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan von Blakkisrud, Johan, Løndalen, Ayca, Martinsen, Anne C T, Dahle, Jostein, Holtedahl, Jon E, Bach-Gansmo, Tore, Holte, Harald, Kolstad, Arne, Stokke, Caroline

Volltext